About: Tavapadon

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Tavapadon (developmental code names CVL-751, PF-6649751, PF-06649751) is a dopamine receptor agonist which is under development by Pfizer and Cerevel Therapeutics for the treatment of Parkinson's disease. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease.

Property	Value
dbo:abstract	Tavapadon (developmental code names CVL-751, PF-6649751, PF-06649751) is a dopamine receptor agonist which is under development by Pfizer and Cerevel Therapeutics for the treatment of Parkinson's disease. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease. (en)
dbo:casNumber	1643489-24-0
dbo:chEMBL	3697617
dbo:fdaUniiCode	PT4P8MJP8L
dbo:kegg	D11431
dbo:pubchem	86764100
dbo:thumbnail	wiki-commons:Special:FilePath/Tavapadon.svg?width=300
dbo:wikiPageID	68797810 (xsd:integer)
dbo:wikiPageLength	3493 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1079552356 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Partial_agonist dbc:D5_receptor_agonists dbr:Pfizer dbc:Diketones dbc:Experimental_drugs dbc:Trifluoromethyl_compounds dbr:Clinical_trial dbc:Biased_ligands dbc:D1-receptor_agonists dbr:Parkinson's_disease dbc:Pyridines dbc:Pyrimidines dbr:Binding_selectivity dbr:Dopamine dbr:Dopamine_receptor_agonist dbr:D1_receptor dbr:D5_receptor dbr:Phases_of_clinical_research dbr:Biased_agonist dbr:G_protein_signaling dbr:Gs_protein
dbp:c	19 (xsd:integer)
dbp:casNumber	1643489 (xsd:integer)
dbp:chembl	3697617 (xsd:integer)
dbp:chemspiderid	48062699 (xsd:integer)
dbp:f	3 (xsd:integer)
dbp:h	16 (xsd:integer)
dbp:iupacName	15 (xsd:integer)
dbp:kegg	D11431 (en)
dbp:n	3 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	86764100 (xsd:integer)
dbp:smiles	CC1=CC3=CC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	AKQXQLUNFKDZBN-UHFFFAOYSA-N (en)
dbp:synonyms	CVL-751; PF-6649751; PF-06649751 (en)
dbp:unii	PT4P8MJP8L (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Dopamine_receptor_modulators
dct:subject	dbc:D5_receptor_agonists dbc:Diketones dbc:Experimental_drugs dbc:Trifluoromethyl_compounds dbc:Biased_ligands dbc:D1-receptor_agonists dbc:Pyridines dbc:Pyrimidines
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Tavapadon (developmental code names CVL-751, PF-6649751, PF-06649751) is a dopamine receptor agonist which is under development by Pfizer and Cerevel Therapeutics for the treatment of Parkinson's disease. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease. (en)
rdfs:label	Tavapadon (en)
owl:sameAs	wikidata:Tavapadon https://global.dbpedia.org/id/G8LJS
prov:wasDerivedFrom	wikipedia-en:Tavapadon?oldid=1079552356&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Tavapadon.svg
foaf:isPrimaryTopicOf	wikipedia-en:Tavapadon
is dbo:wikiPageRedirects of	dbr:PF-06649751 dbr:PF-6649751 dbr:PF06649751 dbr:PF6649751 dbr:PF_06649751 dbr:PF_6649751 dbr:CVL-751 dbr:CVL751 dbr:CVL_751
is dbo:wikiPageWikiLink of	dbr:PF-06649751 dbr:PF-6649751 dbr:PF06649751 dbr:PF6649751 dbr:PF_06649751 dbr:PF_6649751 dbr:CVL-751 dbr:CVL751 dbr:CVL_751
is foaf:primaryTopic of	wikipedia-en:Tavapadon